Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : Morgan Stanley Downgrades Merck & Company to Equalweight from Overweight, Adjusts Price Target to $85 from $90

09/07/2021 | 10:04am EDT


© MT Newswires 2021
All news about MERCK & CO., INC.
07:54aMERCK : Secures European Commission's Approval for Keytruda as Breast Cancer Treatment in ..
MT
06:46aMERCK : European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy a..
BU
05:21aMerck Gets European OK for Keytruda in Triple-Negative Breast Cancer
DJ
01:17aMODERNA : European Medicines Agency's Review for Moderna's COVID-19 Booster Shot Expected ..
MT
10/21MERCK : CDC ACIP Unanimously Votes to Provisionally Recommend Merck's VAXNEUVANCE (Pneumoc..
AQ
10/21MERCK : Bristol-Myers To Shed Acceleron Stake Ahead Of Merck & Co.'s $11.5 Billion Acquisi..
MT
10/20MERCK : British Government Secures COVID-19 Antivirals from Merck & Co., Pfizer
MT
10/20MERCK : CDC ACIP Unanimously Votes to Provisionally Recommend Merck's VAXNEUVANCE™ (..
BU
10/20CDC ACIP Unanimously Votes to Provisionally Recommend Merck?s VAXNEUVANCE?
CI
10/20U.K. in Agreements for Merck/Ridgeback, Pfizer Covid-19 Antivirals in Development
DJ
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 235 M - -
Net income 2021 13 308 M - -
Net Debt 2021 17 557 M - -
P/E ratio 2021 17,1x
Yield 2021 3,19%
Capitalization 205 B 205 B -
EV / Sales 2021 4,62x
EV / Sales 2022 4,07x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 81,17 $
Average target price 94,79 $
Spread / Average Target 16,8%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-0.77%205 472
JOHNSON & JOHNSON3.83%430 148
ROCHE HOLDING AG15.79%339 425
PFIZER, INC.16.27%240 303
NOVO NORDISK A/S56.55%239 079
ELI LILLY AND COMPANY42.84%218 640